0

Close
 
Upcoming Allied Market Research
2023
Cell Therapy Biomanufacturing Market

Cell Therapy Biomanufacturing Market

by Product Type (Consumables, Equipment, Systems Software), by Cell Type (T-cell, Stem Cell, Other Cell), by Process (Cell Processing, Cell Preservation, Distribution, and Handling, Process Monitoring and Quality Control) and by End User (Biopharmaceutical Biotechnology Companies and CROs, Research Institutes and Cell Banks): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13860
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cell Therapy Biomanufacturing Market

Request Now !

Cell therapy bioprocessing is a subfield of bioprocess engineering that bridges cell therapy and biopharmaceutical manufacturing. Cell therapy is one of the fastest-growing areas of the life sciences. It entails delivering entire living cells to a patient to treat chronic and rare disorders. Despite being a niche domain of the biotechnology sector, cell and gene therapy have paved the investments by the contract development and manufacturing organizations (CDMO)/contract manufacturing organizations (CMO).
It involves the delivery of whole, living cells to a patient for the treatment of the disease. Typically, this category is divided into two main sections—autologous, meaning the cells are derived from the patient, and allogenic, meaning the cells are derived from another individual and show some match to the potential new host, similar to a blood transfusion. 

COVID-19 Impact analysis

  • The COVID-19 outbreak is predicted to have a minor or insignificant influence on the market for cell therapy technology. There is a greater need for an effective COVID-19 medicine or vaccination that could help to reduce the severity of the diseases with the growth of COVID-19 instances. Cell-based research is an important step in the production of vaccines, and help boost the growth of the market. The supply chain was disrupted during the early months of the COVID-19 outbreak, which caused the clinical studies to be delayed. This may have a negative impact on the market to some extent. Clinical trial delays have been revealed by biopharmaceutical companies, including significant players such as Pfizer and Eli Lilly.

Top Impacting Factors
The cell therapy biomanufacturing market is predicted to grow due to a greater focus on personalized medicine and increase in public-private partnerships for the development of cell treatments.
An increase in the frequency of cardiovascular illnesses, a rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and the continued development of stem cell therapy methods are the factors propelling the cell therapy biomanufacturing market growth.
Customers and other stakeholders are collaborating with biomanufacturing companies to improve the clinical research and commercial manufacturing of these medicines. This in turn is expected to boost the growth of the cell therapy biomanufacturing market.
Manufacturers' bottlenecks during cell therapy commercialization, high costs involved with cell therapies, and absence of a qualified personnel to run complicated instruments limit the cell therapy biomanufacturing market growth.
Market Trends
New product launches to flourish the market

  • In November 2019, the Australian government released a 10-year roadmap for stem cell research in Australia—The Stem Cell Therapies Mission. The initiative is anticipated to provide USD 102 million (AU$150 million) under the Medical Research Future Fund (MRFF) to support stem cell research to deliver new therapies. 
  • In 2020, Lonza (Switzerland) collaborated with IsoPlexis (U.S.) to develop the next generation of precision cell therapy manufacturing.
  • In 2020, Biopharma business from General Electric Company’s Life Sciences division (U.S.) Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The acquisition led to a new business named Cytiva, a standalone operating company within Danaher’s Life Sciences segment.
  • In 2019, Thermo Fisher Scientific invested ~USD 24 million in its Inchinnan (Scotland) site to expand its global bioproduction capabilities with additional large-volume liquid manufacturing capacity for cell culture media.

Key Benefits of the Report

  • This study presents the analytical depiction of the Cell Therapy Biomanufacturing along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Cell Therapy Biomanufacturing market share.
  • The current market is quantitatively analyzed to highlight the Cell Therapy Biomanufacturing market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed Cell Therapy Biomanufacturing market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Cell Therapy Biomanufacturing Report

  • Who are the leading market players active in the Cell Therapy Biomanufacturing market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is "Cell Therapy Biomanufacturing "?
  • What is "Cell Therapy Biomanufacturing " Market prediction in the future?
  • Who are the leading global players in the "Cell Therapy Biomanufacturing " Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Cell Therapy Biomanufacturing " Market report?

 Cell Therapy Biomanufacturing Market Report Highlights

Aspects Details
By Product Type
  • Consumables
  • Equipment
    • Cell Processing Equipment
    • Single-use Equipment
    • Other Equipment
  • Systems & Software
By Cell Type
  • T-cell
  • Stem Cell
  • Other Cell
By Process
  • Cell Processing
  • Cell Preservation, Distribution, and Handling
  • Process Monitoring and Quality Control
By End User
  • Biopharmaceutical & Biotechnology Companies and CROs
  • Research Institutes and Cell Banks
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Terumo BCT (US), Thermo Fisher Scientific Inc. (US), L7 Informatics, Inc. (US), OrganaBio, LLC (US), Danaher Corporation (US), STEMCELL Technologies (Canada), Dickinson and Company (US), Lonza Group (Switzerland, RoosterBio Inc. (US), Bio-Techne Corporation (US), Avantor, Inc. (US), SIRION Biotech GmbH (Germany), Corning Incorporated (US), Fresenius Medical Care AG & Co. KGaA (Germany), Sartorius AG (Germany), IxCells Biotechnology (China), Wilson Wolf Corporation (US)., MaxCyte (US), MAK-SYSTEM (US), Becton, CellGenix GmbH (Germany), Hemasoft (US), FUJIFILM Irvine Scientific (US), Merck KGaA (Germany). MaxCyte (US), Miltenyi Biotec GmbH (Germany), Werum IT Solutions GmbH (Germany)
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CELL THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Equipment

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Cell Processing Equipment

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Single-use Equipment

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Other Equipment

        • 4.3.4.1. Market Size and Forecast

    • 4.4. Systems Software

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: CELL THERAPY BIOMANUFACTURING MARKET, BY CELL TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Cell Type

    • 5.2. T-cell

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Stem Cell

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Other Cell

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: CELL THERAPY BIOMANUFACTURING MARKET, BY PROCESS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Process

    • 6.2. Cell Processing

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Cell Preservation, Distribution, And Handling

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Process Monitoring And Quality Control

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: CELL THERAPY BIOMANUFACTURING MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Biopharmaceutical Biotechnology Companies And CROs

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Research Institutes And Cell Banks

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

  • CHAPTER 8: CELL THERAPY BIOMANUFACTURING MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product Type

      • 8.2.3. Market Size and Forecast, By Cell Type

      • 8.2.4. Market Size and Forecast, By Process

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Cell Therapy Biomanufacturing Market

        • 8.2.7.1. Market Size and Forecast, By Product Type
        • 8.2.7.2. Market Size and Forecast, By Cell Type
        • 8.2.7.3. Market Size and Forecast, By Process
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Cell Therapy Biomanufacturing Market

        • 8.2.8.1. Market Size and Forecast, By Product Type
        • 8.2.8.2. Market Size and Forecast, By Cell Type
        • 8.2.8.3. Market Size and Forecast, By Process
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Cell Therapy Biomanufacturing Market

        • 8.2.9.1. Market Size and Forecast, By Product Type
        • 8.2.9.2. Market Size and Forecast, By Cell Type
        • 8.2.9.3. Market Size and Forecast, By Process
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product Type

      • 8.3.3. Market Size and Forecast, By Cell Type

      • 8.3.4. Market Size and Forecast, By Process

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Cell Therapy Biomanufacturing Market

        • 8.3.7.1. Market Size and Forecast, By Product Type
        • 8.3.7.2. Market Size and Forecast, By Cell Type
        • 8.3.7.3. Market Size and Forecast, By Process
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Cell Therapy Biomanufacturing Market

        • 8.3.8.1. Market Size and Forecast, By Product Type
        • 8.3.8.2. Market Size and Forecast, By Cell Type
        • 8.3.8.3. Market Size and Forecast, By Process
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Cell Therapy Biomanufacturing Market

        • 8.3.9.1. Market Size and Forecast, By Product Type
        • 8.3.9.2. Market Size and Forecast, By Cell Type
        • 8.3.9.3. Market Size and Forecast, By Process
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Cell Therapy Biomanufacturing Market

        • 8.3.10.1. Market Size and Forecast, By Product Type
        • 8.3.10.2. Market Size and Forecast, By Cell Type
        • 8.3.10.3. Market Size and Forecast, By Process
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Cell Therapy Biomanufacturing Market

        • 8.3.11.1. Market Size and Forecast, By Product Type
        • 8.3.11.2. Market Size and Forecast, By Cell Type
        • 8.3.11.3. Market Size and Forecast, By Process
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Cell Therapy Biomanufacturing Market

        • 8.3.12.1. Market Size and Forecast, By Product Type
        • 8.3.12.2. Market Size and Forecast, By Cell Type
        • 8.3.12.3. Market Size and Forecast, By Process
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Cell Therapy Biomanufacturing Market

        • 8.3.13.1. Market Size and Forecast, By Product Type
        • 8.3.13.2. Market Size and Forecast, By Cell Type
        • 8.3.13.3. Market Size and Forecast, By Process
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product Type

      • 8.4.3. Market Size and Forecast, By Cell Type

      • 8.4.4. Market Size and Forecast, By Process

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Cell Therapy Biomanufacturing Market

        • 8.4.7.1. Market Size and Forecast, By Product Type
        • 8.4.7.2. Market Size and Forecast, By Cell Type
        • 8.4.7.3. Market Size and Forecast, By Process
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Cell Therapy Biomanufacturing Market

        • 8.4.8.1. Market Size and Forecast, By Product Type
        • 8.4.8.2. Market Size and Forecast, By Cell Type
        • 8.4.8.3. Market Size and Forecast, By Process
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Cell Therapy Biomanufacturing Market

        • 8.4.9.1. Market Size and Forecast, By Product Type
        • 8.4.9.2. Market Size and Forecast, By Cell Type
        • 8.4.9.3. Market Size and Forecast, By Process
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Cell Therapy Biomanufacturing Market

        • 8.4.10.1. Market Size and Forecast, By Product Type
        • 8.4.10.2. Market Size and Forecast, By Cell Type
        • 8.4.10.3. Market Size and Forecast, By Process
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Cell Therapy Biomanufacturing Market

        • 8.4.11.1. Market Size and Forecast, By Product Type
        • 8.4.11.2. Market Size and Forecast, By Cell Type
        • 8.4.11.3. Market Size and Forecast, By Process
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Cell Therapy Biomanufacturing Market

        • 8.4.12.1. Market Size and Forecast, By Product Type
        • 8.4.12.2. Market Size and Forecast, By Cell Type
        • 8.4.12.3. Market Size and Forecast, By Process
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Cell Therapy Biomanufacturing Market

        • 8.4.13.1. Market Size and Forecast, By Product Type
        • 8.4.13.2. Market Size and Forecast, By Cell Type
        • 8.4.13.3. Market Size and Forecast, By Process
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Cell Therapy Biomanufacturing Market

        • 8.4.14.1. Market Size and Forecast, By Product Type
        • 8.4.14.2. Market Size and Forecast, By Cell Type
        • 8.4.14.3. Market Size and Forecast, By Process
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Cell Therapy Biomanufacturing Market

        • 8.4.15.1. Market Size and Forecast, By Product Type
        • 8.4.15.2. Market Size and Forecast, By Cell Type
        • 8.4.15.3. Market Size and Forecast, By Process
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product Type

      • 8.5.3. Market Size and Forecast, By Cell Type

      • 8.5.4. Market Size and Forecast, By Process

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Cell Therapy Biomanufacturing Market

        • 8.5.7.1. Market Size and Forecast, By Product Type
        • 8.5.7.2. Market Size and Forecast, By Cell Type
        • 8.5.7.3. Market Size and Forecast, By Process
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Cell Therapy Biomanufacturing Market

        • 8.5.8.1. Market Size and Forecast, By Product Type
        • 8.5.8.2. Market Size and Forecast, By Cell Type
        • 8.5.8.3. Market Size and Forecast, By Process
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Cell Therapy Biomanufacturing Market

        • 8.5.9.1. Market Size and Forecast, By Product Type
        • 8.5.9.2. Market Size and Forecast, By Cell Type
        • 8.5.9.3. Market Size and Forecast, By Process
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Cell Therapy Biomanufacturing Market

        • 8.5.10.1. Market Size and Forecast, By Product Type
        • 8.5.10.2. Market Size and Forecast, By Cell Type
        • 8.5.10.3. Market Size and Forecast, By Process
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Cell Therapy Biomanufacturing Market

        • 8.5.11.1. Market Size and Forecast, By Product Type
        • 8.5.11.2. Market Size and Forecast, By Cell Type
        • 8.5.11.3. Market Size and Forecast, By Process
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Cell Therapy Biomanufacturing Market

        • 8.5.12.1. Market Size and Forecast, By Product Type
        • 8.5.12.2. Market Size and Forecast, By Cell Type
        • 8.5.12.3. Market Size and Forecast, By Process
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Thermo Fisher Scientific Inc. (US)

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Merck KGaA (Germany). MaxCyte (US)

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Danaher Corporation (US)

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Becton

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Dickinson And Company (US)

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Lonza Group (Switzerland

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Sartorius AG (Germany)

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Terumo BCT (US)

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Fresenius Medical Care AG And Co. KGaA (Germany)

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Avantor, Inc. (US)

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. Bio-Techne Corporation (US)

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

    • 10.12. Corning Incorporated (US)

      • 10.12.1. Company Overview

      • 10.12.2. Key Executives

      • 10.12.3. Company Snapshot

      • 10.12.4. Operating Business Segments

      • 10.12.5. Product Portfolio

      • 10.12.6. Business Performance

      • 10.12.7. Key Strategic Moves and Developments

    • 10.13. FUJIFILM Irvine Scientific (US)

      • 10.13.1. Company Overview

      • 10.13.2. Key Executives

      • 10.13.3. Company Snapshot

      • 10.13.4. Operating Business Segments

      • 10.13.5. Product Portfolio

      • 10.13.6. Business Performance

      • 10.13.7. Key Strategic Moves and Developments

    • 10.14. MaxCyte (US)

      • 10.14.1. Company Overview

      • 10.14.2. Key Executives

      • 10.14.3. Company Snapshot

      • 10.14.4. Operating Business Segments

      • 10.14.5. Product Portfolio

      • 10.14.6. Business Performance

      • 10.14.7. Key Strategic Moves and Developments

    • 10.15. Werum IT Solutions GmbH (Germany)

      • 10.15.1. Company Overview

      • 10.15.2. Key Executives

      • 10.15.3. Company Snapshot

      • 10.15.4. Operating Business Segments

      • 10.15.5. Product Portfolio

      • 10.15.6. Business Performance

      • 10.15.7. Key Strategic Moves and Developments

    • 10.16. RoosterBio Inc. (US)

      • 10.16.1. Company Overview

      • 10.16.2. Key Executives

      • 10.16.3. Company Snapshot

      • 10.16.4. Operating Business Segments

      • 10.16.5. Product Portfolio

      • 10.16.6. Business Performance

      • 10.16.7. Key Strategic Moves and Developments

    • 10.17. SIRION Biotech GmbH (Germany)

      • 10.17.1. Company Overview

      • 10.17.2. Key Executives

      • 10.17.3. Company Snapshot

      • 10.17.4. Operating Business Segments

      • 10.17.5. Product Portfolio

      • 10.17.6. Business Performance

      • 10.17.7. Key Strategic Moves and Developments

    • 10.18. CellGenix GmbH (Germany)

      • 10.18.1. Company Overview

      • 10.18.2. Key Executives

      • 10.18.3. Company Snapshot

      • 10.18.4. Operating Business Segments

      • 10.18.5. Product Portfolio

      • 10.18.6. Business Performance

      • 10.18.7. Key Strategic Moves and Developments

    • 10.19. L7 Informatics, Inc. (US)

      • 10.19.1. Company Overview

      • 10.19.2. Key Executives

      • 10.19.3. Company Snapshot

      • 10.19.4. Operating Business Segments

      • 10.19.5. Product Portfolio

      • 10.19.6. Business Performance

      • 10.19.7. Key Strategic Moves and Developments

    • 10.20. Miltenyi Biotec GmbH (Germany)

      • 10.20.1. Company Overview

      • 10.20.2. Key Executives

      • 10.20.3. Company Snapshot

      • 10.20.4. Operating Business Segments

      • 10.20.5. Product Portfolio

      • 10.20.6. Business Performance

      • 10.20.7. Key Strategic Moves and Developments

    • 10.21. STEMCELL Technologies (Canada)

      • 10.21.1. Company Overview

      • 10.21.2. Key Executives

      • 10.21.3. Company Snapshot

      • 10.21.4. Operating Business Segments

      • 10.21.5. Product Portfolio

      • 10.21.6. Business Performance

      • 10.21.7. Key Strategic Moves and Developments

    • 10.22. Hemasoft (US)

      • 10.22.1. Company Overview

      • 10.22.2. Key Executives

      • 10.22.3. Company Snapshot

      • 10.22.4. Operating Business Segments

      • 10.22.5. Product Portfolio

      • 10.22.6. Business Performance

      • 10.22.7. Key Strategic Moves and Developments

    • 10.23. MAK-SYSTEM (US)

      • 10.23.1. Company Overview

      • 10.23.2. Key Executives

      • 10.23.3. Company Snapshot

      • 10.23.4. Operating Business Segments

      • 10.23.5. Product Portfolio

      • 10.23.6. Business Performance

      • 10.23.7. Key Strategic Moves and Developments

    • 10.24. OrganaBio, LLC (US)

      • 10.24.1. Company Overview

      • 10.24.2. Key Executives

      • 10.24.3. Company Snapshot

      • 10.24.4. Operating Business Segments

      • 10.24.5. Product Portfolio

      • 10.24.6. Business Performance

      • 10.24.7. Key Strategic Moves and Developments

    • 10.25. IxCells Biotechnology (China)

      • 10.25.1. Company Overview

      • 10.25.2. Key Executives

      • 10.25.3. Company Snapshot

      • 10.25.4. Operating Business Segments

      • 10.25.5. Product Portfolio

      • 10.25.6. Business Performance

      • 10.25.7. Key Strategic Moves and Developments

    • 10.26. Wilson Wolf Corporation (US).

      • 10.26.1. Company Overview

      • 10.26.2. Key Executives

      • 10.26.3. Company Snapshot

      • 10.26.4. Operating Business Segments

      • 10.26.5. Product Portfolio

      • 10.26.6. Business Performance

      • 10.26.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR EQUIPMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR SYSTEMS SOFTWARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR T-CELL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR STEM CELL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR OTHER CELL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR CELL PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR BIOPHARMACEUTICAL BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA CELL THERAPY BIOMANUFACTURING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. U.S. CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 24. U.S. CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 25. U.S. CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. CANADA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 28. CANADA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 29. CANADA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE CELL THERAPY BIOMANUFACTURING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 41. FRANCE CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. GERMANY CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 45. GERMANY CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. ITALY CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. ITALY CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 49. ITALY CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 50. ITALY CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. SPAIN CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. SPAIN CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 53. SPAIN CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. UK CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. UK CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 57. UK CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 58. UK CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. RUSSIA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. RUSSIA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 61. RUSSIA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. REST OF EUROPE CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. REST OF EUROPE CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 65. REST OF EUROPE CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 68. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. CHINA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 73. CHINA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 74. CHINA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 75. CHINA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. JAPAN CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 77. JAPAN CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 78. JAPAN CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. INDIA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. INDIA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 82. INDIA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 83. INDIA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH KOREA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH KOREA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH KOREA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. AUSTRALIA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 89. AUSTRALIA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 90. AUSTRALIA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 92. THAILAND CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 93. THAILAND CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 94. THAILAND CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. MALAYSIA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 97. MALAYSIA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 98. MALAYSIA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. INDONESIA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. INDONESIA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 102. INDONESIA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 104. REST OF ASIA PACIFIC CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 105. REST OF ASIA PACIFIC CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 106. REST OF ASIA PACIFIC CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 108. LAMEA CELL THERAPY BIOMANUFACTURING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 109. LAMEA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 110. LAMEA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 113. BRAZIL CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 114. BRAZIL CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 115. BRAZIL CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 117. SOUTH AFRICA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 118. SOUTH AFRICA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 119. SOUTH AFRICA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 121. SAUDI ARABIA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 122. SAUDI ARABIA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 123. SAUDI ARABIA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 125. UAE CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 126. UAE CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 127. UAE CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 128. UAE CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 129. ARGENTINA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 130. ARGENTINA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 131. ARGENTINA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 133. REST OF LAMEA CELL THERAPY BIOMANUFACTURING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 134. REST OF LAMEA CELL THERAPY BIOMANUFACTURING, BY CELL TYPE, 2022-2032 ($MILLION)
  • TABLE 135. REST OF LAMEA CELL THERAPY BIOMANUFACTURING, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA CELL THERAPY BIOMANUFACTURING, BY END USER, 2022-2032 ($MILLION)
  • TABLE 137. THERMO FISHER SCIENTIFIC INC. (US): KEY EXECUTIVES
  • TABLE 138. THERMO FISHER SCIENTIFIC INC. (US): COMPANY SNAPSHOT
  • TABLE 139. THERMO FISHER SCIENTIFIC INC. (US): OPERATING SEGMENTS
  • TABLE 140. THERMO FISHER SCIENTIFIC INC. (US): PRODUCT PORTFOLIO
  • TABLE 141. THERMO FISHER SCIENTIFIC INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. MERCK KGAA (GERMANY). MAXCYTE (US): KEY EXECUTIVES
  • TABLE 143. MERCK KGAA (GERMANY). MAXCYTE (US): COMPANY SNAPSHOT
  • TABLE 144. MERCK KGAA (GERMANY). MAXCYTE (US): OPERATING SEGMENTS
  • TABLE 145. MERCK KGAA (GERMANY). MAXCYTE (US): PRODUCT PORTFOLIO
  • TABLE 146. MERCK KGAA (GERMANY). MAXCYTE (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. DANAHER CORPORATION (US): KEY EXECUTIVES
  • TABLE 148. DANAHER CORPORATION (US): COMPANY SNAPSHOT
  • TABLE 149. DANAHER CORPORATION (US): OPERATING SEGMENTS
  • TABLE 150. DANAHER CORPORATION (US): PRODUCT PORTFOLIO
  • TABLE 151. DANAHER CORPORATION (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. BECTON: KEY EXECUTIVES
  • TABLE 153. BECTON: COMPANY SNAPSHOT
  • TABLE 154. BECTON: OPERATING SEGMENTS
  • TABLE 155. BECTON: PRODUCT PORTFOLIO
  • TABLE 156. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. DICKINSON AND COMPANY (US): KEY EXECUTIVES
  • TABLE 158. DICKINSON AND COMPANY (US): COMPANY SNAPSHOT
  • TABLE 159. DICKINSON AND COMPANY (US): OPERATING SEGMENTS
  • TABLE 160. DICKINSON AND COMPANY (US): PRODUCT PORTFOLIO
  • TABLE 161. DICKINSON AND COMPANY (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162. LONZA GROUP (SWITZERLAND: KEY EXECUTIVES
  • TABLE 163. LONZA GROUP (SWITZERLAND: COMPANY SNAPSHOT
  • TABLE 164. LONZA GROUP (SWITZERLAND: OPERATING SEGMENTS
  • TABLE 165. LONZA GROUP (SWITZERLAND: PRODUCT PORTFOLIO
  • TABLE 166. LONZA GROUP (SWITZERLAND: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 167. SARTORIUS AG (GERMANY): KEY EXECUTIVES
  • TABLE 168. SARTORIUS AG (GERMANY): COMPANY SNAPSHOT
  • TABLE 169. SARTORIUS AG (GERMANY): OPERATING SEGMENTS
  • TABLE 170. SARTORIUS AG (GERMANY): PRODUCT PORTFOLIO
  • TABLE 171. SARTORIUS AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 172. TERUMO BCT (US): KEY EXECUTIVES
  • TABLE 173. TERUMO BCT (US): COMPANY SNAPSHOT
  • TABLE 174. TERUMO BCT (US): OPERATING SEGMENTS
  • TABLE 175. TERUMO BCT (US): PRODUCT PORTFOLIO
  • TABLE 176. TERUMO BCT (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): KEY EXECUTIVES
  • TABLE 178. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): COMPANY SNAPSHOT
  • TABLE 179. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): OPERATING SEGMENTS
  • TABLE 180. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): PRODUCT PORTFOLIO
  • TABLE 181. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. AVANTOR, INC. (US): KEY EXECUTIVES
  • TABLE 183. AVANTOR, INC. (US): COMPANY SNAPSHOT
  • TABLE 184. AVANTOR, INC. (US): OPERATING SEGMENTS
  • TABLE 185. AVANTOR, INC. (US): PRODUCT PORTFOLIO
  • TABLE 186. AVANTOR, INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. BIO-TECHNE CORPORATION (US): KEY EXECUTIVES
  • TABLE 188. BIO-TECHNE CORPORATION (US): COMPANY SNAPSHOT
  • TABLE 189. BIO-TECHNE CORPORATION (US): OPERATING SEGMENTS
  • TABLE 190. BIO-TECHNE CORPORATION (US): PRODUCT PORTFOLIO
  • TABLE 191. BIO-TECHNE CORPORATION (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 192. CORNING INCORPORATED (US): KEY EXECUTIVES
  • TABLE 193. CORNING INCORPORATED (US): COMPANY SNAPSHOT
  • TABLE 194. CORNING INCORPORATED (US): OPERATING SEGMENTS
  • TABLE 195. CORNING INCORPORATED (US): PRODUCT PORTFOLIO
  • TABLE 196. CORNING INCORPORATED (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 197. FUJIFILM IRVINE SCIENTIFIC (US): KEY EXECUTIVES
  • TABLE 198. FUJIFILM IRVINE SCIENTIFIC (US): COMPANY SNAPSHOT
  • TABLE 199. FUJIFILM IRVINE SCIENTIFIC (US): OPERATING SEGMENTS
  • TABLE 200. FUJIFILM IRVINE SCIENTIFIC (US): PRODUCT PORTFOLIO
  • TABLE 201. FUJIFILM IRVINE SCIENTIFIC (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 202. MAXCYTE (US): KEY EXECUTIVES
  • TABLE 203. MAXCYTE (US): COMPANY SNAPSHOT
  • TABLE 204. MAXCYTE (US): OPERATING SEGMENTS
  • TABLE 205. MAXCYTE (US): PRODUCT PORTFOLIO
  • TABLE 206. MAXCYTE (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 207. WERUM IT SOLUTIONS GMBH (GERMANY): KEY EXECUTIVES
  • TABLE 208. WERUM IT SOLUTIONS GMBH (GERMANY): COMPANY SNAPSHOT
  • TABLE 209. WERUM IT SOLUTIONS GMBH (GERMANY): OPERATING SEGMENTS
  • TABLE 210. WERUM IT SOLUTIONS GMBH (GERMANY): PRODUCT PORTFOLIO
  • TABLE 211. WERUM IT SOLUTIONS GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 212. ROOSTERBIO INC. (US): KEY EXECUTIVES
  • TABLE 213. ROOSTERBIO INC. (US): COMPANY SNAPSHOT
  • TABLE 214. ROOSTERBIO INC. (US): OPERATING SEGMENTS
  • TABLE 215. ROOSTERBIO INC. (US): PRODUCT PORTFOLIO
  • TABLE 216. ROOSTERBIO INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 217. SIRION BIOTECH GMBH (GERMANY): KEY EXECUTIVES
  • TABLE 218. SIRION BIOTECH GMBH (GERMANY): COMPANY SNAPSHOT
  • TABLE 219. SIRION BIOTECH GMBH (GERMANY): OPERATING SEGMENTS
  • TABLE 220. SIRION BIOTECH GMBH (GERMANY): PRODUCT PORTFOLIO
  • TABLE 221. SIRION BIOTECH GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 222. CELLGENIX GMBH (GERMANY): KEY EXECUTIVES
  • TABLE 223. CELLGENIX GMBH (GERMANY): COMPANY SNAPSHOT
  • TABLE 224. CELLGENIX GMBH (GERMANY): OPERATING SEGMENTS
  • TABLE 225. CELLGENIX GMBH (GERMANY): PRODUCT PORTFOLIO
  • TABLE 226. CELLGENIX GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 227. L7 INFORMATICS, INC. (US): KEY EXECUTIVES
  • TABLE 228. L7 INFORMATICS, INC. (US): COMPANY SNAPSHOT
  • TABLE 229. L7 INFORMATICS, INC. (US): OPERATING SEGMENTS
  • TABLE 230. L7 INFORMATICS, INC. (US): PRODUCT PORTFOLIO
  • TABLE 231. L7 INFORMATICS, INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 232. MILTENYI BIOTEC GMBH (GERMANY): KEY EXECUTIVES
  • TABLE 233. MILTENYI BIOTEC GMBH (GERMANY): COMPANY SNAPSHOT
  • TABLE 234. MILTENYI BIOTEC GMBH (GERMANY): OPERATING SEGMENTS
  • TABLE 235. MILTENYI BIOTEC GMBH (GERMANY): PRODUCT PORTFOLIO
  • TABLE 236. MILTENYI BIOTEC GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 237. STEMCELL TECHNOLOGIES (CANADA): KEY EXECUTIVES
  • TABLE 238. STEMCELL TECHNOLOGIES (CANADA): COMPANY SNAPSHOT
  • TABLE 239. STEMCELL TECHNOLOGIES (CANADA): OPERATING SEGMENTS
  • TABLE 240. STEMCELL TECHNOLOGIES (CANADA): PRODUCT PORTFOLIO
  • TABLE 241. STEMCELL TECHNOLOGIES (CANADA): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 242. HEMASOFT (US): KEY EXECUTIVES
  • TABLE 243. HEMASOFT (US): COMPANY SNAPSHOT
  • TABLE 244. HEMASOFT (US): OPERATING SEGMENTS
  • TABLE 245. HEMASOFT (US): PRODUCT PORTFOLIO
  • TABLE 246. HEMASOFT (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 247. MAK-SYSTEM (US): KEY EXECUTIVES
  • TABLE 248. MAK-SYSTEM (US): COMPANY SNAPSHOT
  • TABLE 249. MAK-SYSTEM (US): OPERATING SEGMENTS
  • TABLE 250. MAK-SYSTEM (US): PRODUCT PORTFOLIO
  • TABLE 251. MAK-SYSTEM (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 252. ORGANABIO, LLC (US): KEY EXECUTIVES
  • TABLE 253. ORGANABIO, LLC (US): COMPANY SNAPSHOT
  • TABLE 254. ORGANABIO, LLC (US): OPERATING SEGMENTS
  • TABLE 255. ORGANABIO, LLC (US): PRODUCT PORTFOLIO
  • TABLE 256. ORGANABIO, LLC (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 257. IXCELLS BIOTECHNOLOGY (CHINA): KEY EXECUTIVES
  • TABLE 258. IXCELLS BIOTECHNOLOGY (CHINA): COMPANY SNAPSHOT
  • TABLE 259. IXCELLS BIOTECHNOLOGY (CHINA): OPERATING SEGMENTS
  • TABLE 260. IXCELLS BIOTECHNOLOGY (CHINA): PRODUCT PORTFOLIO
  • TABLE 261. IXCELLS BIOTECHNOLOGY (CHINA): KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 262. WILSON WOLF CORPORATION (US).: KEY EXECUTIVES
  • TABLE 263. WILSON WOLF CORPORATION (US).: COMPANY SNAPSHOT
  • TABLE 264. WILSON WOLF CORPORATION (US).: OPERATING SEGMENTS
  • TABLE 265. WILSON WOLF CORPORATION (US).: PRODUCT PORTFOLIO
  • TABLE 266. WILSON WOLF CORPORATION (US).: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET
  • FIGURE 3. SEGMENTATION CELL THERAPY BIOMANUFACTURING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CELL THERAPY BIOMANUFACTURING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCELL THERAPY BIOMANUFACTURING MARKET
  • FIGURE 11. CELL THERAPY BIOMANUFACTURING MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. CELL THERAPY BIOMANUFACTURING MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CELL THERAPY BIOMANUFACTURING MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CELL THERAPY BIOMANUFACTURING MARKET FOR SYSTEMS SOFTWARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CELL THERAPY BIOMANUFACTURING MARKET SEGMENTATION, BY BY CELL TYPE
  • FIGURE 16. CELL THERAPY BIOMANUFACTURING MARKET FOR T-CELL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CELL THERAPY BIOMANUFACTURING MARKET FOR STEM CELL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CELL THERAPY BIOMANUFACTURING MARKET FOR OTHER CELL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. CELL THERAPY BIOMANUFACTURING MARKET SEGMENTATION, BY BY PROCESS
  • FIGURE 20. CELL THERAPY BIOMANUFACTURING MARKET FOR CELL PROCESSING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. CELL THERAPY BIOMANUFACTURING MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. CELL THERAPY BIOMANUFACTURING MARKET FOR PROCESS MONITORING AND QUALITY CONTROL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. CELL THERAPY BIOMANUFACTURING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 24. CELL THERAPY BIOMANUFACTURING MARKET FOR BIOPHARMACEUTICAL BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. CELL THERAPY BIOMANUFACTURING MARKET FOR RESEARCH INSTITUTES AND CELL BANKS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: CELL THERAPY BIOMANUFACTURING MARKET
  • FIGURE 32. Top player positioning, 2022
  • FIGURE 33. THERMO FISHER SCIENTIFIC INC. (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. THERMO FISHER SCIENTIFIC INC. (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. THERMO FISHER SCIENTIFIC INC. (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. MERCK KGAA (GERMANY). MAXCYTE (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. MERCK KGAA (GERMANY). MAXCYTE (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. MERCK KGAA (GERMANY). MAXCYTE (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. DANAHER CORPORATION (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. DANAHER CORPORATION (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. DANAHER CORPORATION (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. BECTON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. BECTON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. BECTON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. DICKINSON AND COMPANY (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. DICKINSON AND COMPANY (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. DICKINSON AND COMPANY (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. LONZA GROUP (SWITZERLAND: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. LONZA GROUP (SWITZERLAND: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. LONZA GROUP (SWITZERLAND: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. SARTORIUS AG (GERMANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. SARTORIUS AG (GERMANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. SARTORIUS AG (GERMANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. TERUMO BCT (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. TERUMO BCT (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. TERUMO BCT (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. FRESENIUS MEDICAL CARE AG AND CO. KGAA (GERMANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. AVANTOR, INC. (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. AVANTOR, INC. (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. AVANTOR, INC. (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. BIO-TECHNE CORPORATION (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. BIO-TECHNE CORPORATION (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. BIO-TECHNE CORPORATION (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. CORNING INCORPORATED (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. CORNING INCORPORATED (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. CORNING INCORPORATED (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. FUJIFILM IRVINE SCIENTIFIC (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. FUJIFILM IRVINE SCIENTIFIC (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. FUJIFILM IRVINE SCIENTIFIC (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 72. MAXCYTE (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 73. MAXCYTE (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 74. MAXCYTE (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 75. WERUM IT SOLUTIONS GMBH (GERMANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 76. WERUM IT SOLUTIONS GMBH (GERMANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 77. WERUM IT SOLUTIONS GMBH (GERMANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 78. ROOSTERBIO INC. (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 79. ROOSTERBIO INC. (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 80. ROOSTERBIO INC. (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 81. SIRION BIOTECH GMBH (GERMANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 82. SIRION BIOTECH GMBH (GERMANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 83. SIRION BIOTECH GMBH (GERMANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 84. CELLGENIX GMBH (GERMANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 85. CELLGENIX GMBH (GERMANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 86. CELLGENIX GMBH (GERMANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 87. L7 INFORMATICS, INC. (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 88. L7 INFORMATICS, INC. (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 89. L7 INFORMATICS, INC. (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 90. MILTENYI BIOTEC GMBH (GERMANY): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 91. MILTENYI BIOTEC GMBH (GERMANY): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 92. MILTENYI BIOTEC GMBH (GERMANY): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 93. STEMCELL TECHNOLOGIES (CANADA): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 94. STEMCELL TECHNOLOGIES (CANADA): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 95. STEMCELL TECHNOLOGIES (CANADA): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 96. HEMASOFT (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 97. HEMASOFT (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 98. HEMASOFT (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 99. MAK-SYSTEM (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 100. MAK-SYSTEM (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 101. MAK-SYSTEM (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 102. ORGANABIO, LLC (US): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 103. ORGANABIO, LLC (US): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 104. ORGANABIO, LLC (US): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 105. IXCELLS BIOTECHNOLOGY (CHINA): NET SALES, 2020-2022 ($MILLION)
  • FIGURE 106. IXCELLS BIOTECHNOLOGY (CHINA): REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 107. IXCELLS BIOTECHNOLOGY (CHINA): REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 108. WILSON WOLF CORPORATION (US).: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 109. WILSON WOLF CORPORATION (US).: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 110. WILSON WOLF CORPORATION (US).: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Cell Therapy Biomanufacturing Market

Start reading.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers